Information Provided By: 
Fly News Breaks for January 10, 2020
MRNS
Jan 10, 2020 | 07:07 EDT
H.C. Wainwright analyst Douglas Tsao raised his price target for Marinus Pharmaceuticals to $6 from $5 saying the $70M equity offering provided "needed investor confidence that the company could fund the numerous opportunities for ganaxolone." This addressed what had been an "acute overhang on shares despite the compelling data" in refractory status epilepticus that the company released in November, Tsao tells investors in a research note. The analyst reiterates a Buy rating on the shares.
News For MRNS From the Last 2 Days
There are no results for your query MRNS
